SEC Filing Summary: StemCells, Inc. (Form 10-K)
Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Period: Fiscal year ended December 31, 2008
Business Overview: StemCells, Inc. is a biopharmaceutical company developing cell-based therapeutics for degenerative diseases. The company operates two primary programs: the CNS Program (developing HuCNS-SC neural stem cells for disorders like Batten disease and Pelizaeus-Merzbacher Disease) and the Liver Program (developing human liver engrafting cells). The company has no approved products and relies on external financing and grants.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $232,000 | $57,000 |
| Net Loss | $(29,087,000) | $(25,023,000) |
| Loss Per Share (Basic/Diluted) | $(0.35) | $(0.31) |
| Research & Development Expenses | $17,808,000 | $19,937,000 |
| General & Administrative Expenses | $8,296,000 | $7,927,000 |
| Cash and Cash Equivalents (End of Period) | $30,043,000 | $9,759,000 |
| Total Assets | $41,230,000 | $48,283,000 |
| Long-Term Debt | $867,000 | $1,034,000 |
| Warrant Liability (Fair Value) | $8,440,000 | $0 |
Note: The company recorded a $2.08 million other-than-temporary impairment loss on ReNeuron equity securities and a $937,000 loss on the change in fair value of warrant liability in 2008.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 309% to $232,000, driven by a $150,000 milestone payment and a $305,000 NIH grant (of which $26,000 was recognized in 2008).
- Net Loss Expansion: Net loss increased by approximately $4 million compared to 2007. This was primarily due to non-cash charges: a $2.08 million impairment of ReNeuron securities and a $937,000 loss on warrant liability valuation.
- Operating Expenses: Total operating expenses decreased by 6% to $26.97 million. R&D expenses dropped 11% due to the completion of the Phase I NCL trial enrollment and reduced external services.
- Liquidity: Cash and cash equivalents increased significantly from $9.76 million to $30.04 million, primarily due to a November 2008 equity financing that raised approximately $18.6 million net.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Progress: Completed a six-patient Phase I trial for Batten disease (NCL) in January 2009; results expected mid-2009. Received FDA authorization in December 2008 to initiate a Phase I trial for Pelizaeus-Merzbacher Disease (PMD), expected to begin in 2009.
- Acquisition: In March 2009, the company entered an agreement to acquire Stem Cell Sciences Plc (SCS) for 2.65 million shares of common stock, aiming to diversify into cell-based assays and drug discovery.
- Capital Needs: Management states that existing capital resources may not be sufficient to fund operations beyond the next twelve months. Additional equity or debt financing will be required.
- Risks: Significant risks include the failure of clinical trials, inability to raise capital, and the high cost of maintaining a former Rhode Island facility (wind-down reserve of $5.5 million). The company is also engaged in patent infringement litigation against Neuralstem, Inc.
- Unusual Items: The $2.08 million impairment of ReNeuron stock and the $937,000 warrant liability loss were significant non-operating charges impacting the bottom line.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure additional financing given the statement that cash may not last beyond 12 months.
- Clinical Trial Results: Monitor the mid-2009 release of data from the NCL Phase I trial, which is critical for future funding and valuation.
- Acquisition Dilution: Assess the impact of the 2.65 million shares to be issued for the SCS acquisition on existing shareholders.
- Wind-Down Costs: Review the assumptions regarding the Rhode Island facility lease (expiring 2013) and the $5.5 million reserve, as changes in sublease occupancy could materially affect expenses.
- Patent Litigation: Track the status of the patent infringement suits against Neuralstem, Inc., which could impact the company's IP portfolio and incur significant legal costs.